Inclusion Criteria:  ≥ 18 years old Diagnosed HIV At least 6 months of ongoing treatment with dolutegravir/ abacavir/lamivudine Plasma viral load (HIV-RNA) < 50 copies/ml at inclusion  For women of childbearing potential:  Negative pregnancy test Willingness to use contraceptive (consistent with local regulations) during study period  Exclusion Criteria:  Pre-existing viral resistance mutations to lamivudine or to dolutegravir Presence of hepatitis B antigen (HBsAg) or Hepatitis B virus DNA (HBV DNA) Cancer within past 5 years Diabetes, cardiovascular disease or other chronic illness considered stable as assessed by the treating physician  For women of childbearing potential:  Pregnancy Breastfeeding